{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:13:02Z","timestamp":1778634782788,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Finnish Institute for Health and Welfare"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Elevated lipoprotein(a) [Lp(a)] is an important genetic risk factor for cardiovascular diseases (CVDs). Because Lp(a)-lowering therapies are limited, prevention focuses on identifying individuals with elevated Lp(a) and optimizing other modifiable risk factors. We aimed to assess the distribution of Lp(a) levels in Finnish adults and examine its association with other CVD risk factors, as well as the awareness, treatment, and control of dyslipidemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were derived from the Healthy Finland health examination survey conducted in 2023, comprising a nationally representative sample of 5,484 adults. Lp(a) levels were categorized using a cut-point at 125 nmol\/L. Other CVD risk factors included were dyslipidemia, abnormal glucose metabolism, hypertension, and obesity. Analyses were weighted taking into account the sampling design and non-participation to provide nationally representative results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mean Lp(a) levels were 41.7 nmol\/L (95% CI 39.0\u201344.3) in men (M) and 41.9 nmol\/L (39.7\u201344.1) in women (W). Elevated Lp(a) was observed in 11.0% of men and 10.4% of women. Dyslipidemia was more prevalent among individuals with elevated Lp(a) (M: 88.1% vs. 78.4%\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003, W: 79.2% vs. 73.2%\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.030) but this association reversed after correcting cholesterol for Lp(a). No associations were found between Lp(a) and other cardiometabolic risk factors. Individuals with elevated Lp(a) had slightly lower unawareness (M: 42.3% vs. 47.5%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.180, W: 38.8% vs.48.4%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.042) and better treatment (M: 38.1% vs. 31.7%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.010, W: 29.2% vs. 24.7%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.090) of dyslipidemia than those with lower levels while no association was found between Lp(a) and dyslipidemia control (M: 81.4% vs. 84.1%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.520, W: 74.6% vs. 73.0%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.740).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Approximately one in ten Finnish adults had elevated Lp(a), a lower prevalence than in many other European populations but still affecting a substantial share of the population. Elevated Lp(a) was associated with higher prevalence of dyslipidemia prior to Lp(a) correction, but not with other CVD risk factors, and these individuals also showed slightly greater awareness and treatment of dyslipidemia. These findings emphasize the need for comprehensive management of modifiable CVD risk factors to reduce the overall burden of CVDs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12944-026-02938-x","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:38:04Z","timestamp":1775090284000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lipoprotein(a) levels in Finnish adults: distribution and associations with other cardiovascular risk factors and their awareness and control"],"prefix":"10.1186","volume":"25","author":[{"given":"Alpo","family":"Vuorio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anniina","family":"Ojanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarja","family":"Palosaari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuija","family":"J\u00e4\u00e4skel\u00e4inen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pekka","family":"Jousilahti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maija","family":"Ruuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terhi","family":"Vihervaara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"Savolainen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Lehtoranta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petri T","family":"Kovanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annamari","family":"Lundqvist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"2938_CR1","doi-asserted-by":"publisher","unstructured":"Reyes-Soffer G, Ginsberg HN, Berglund L, et al. A genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: A scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(1). https:\/\/doi.org\/10.1161\/ATV.0000000000000147.","DOI":"10.1161\/ATV.0000000000000147"},{"issue":"2","key":"2938_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s00392-024-02420-7","volume":"113","author":"R Yang","year":"2024","unstructured":"Yang R, Wu S, Zhao Z, et al. Causal association between lipoproteins and risk of coronary artery disease\u2014a systematic review and meta-analysis of Mendelian randomization studies. Clin Res Cardiol. 2024;113(2):134\u201345. https:\/\/doi.org\/10.1007\/s00392-024-02420-7.","journal-title":"Clin Res Cardiol"},{"issue":"5","key":"2938_CR3","doi-asserted-by":"publisher","first-page":"oeae066","DOI":"10.1093\/ehjopen\/oeae066","volume":"4","author":"S Surma","year":"2024","unstructured":"Surma S, Sosnowska B, Reiner \u017d, Banach M. New data allow to better understand the secrets of lipoprotein(a): is that for sure? Eur Heart J Open. 2024;4(5):oeae066. https:\/\/doi.org\/10.1093\/ehjopen\/oeae066.","journal-title":"Eur Heart J Open"},{"issue":"2","key":"2938_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jacl.2023.12.005","volume":"18","author":"HS Bhatia","year":"2024","unstructured":"Bhatia HS, Wandel S, Willeit P, et al. Lipoprotein(a) and cardiovascular risk: a meta-analysis of randomized controlled trials and observational studies. J Clin Lipidol. 2024;18(2):123\u201334. https:\/\/doi.org\/10.1016\/j.jacl.2023.12.005.","journal-title":"J Clin Lipidol"},{"issue":"5","key":"2938_CR5","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1093\/eurheartj\/ehac361","volume":"44","author":"R Verbeek","year":"2023","unstructured":"Verbeek R, Hoogeveen RM, Langsted A, et al. Lipoprotein(a) and risk of cardiovascular disease: synergistic effects with other risk factors in a meta-analysis of prospective studies. Eur Heart J. 2023;44(5):987\u201396. https:\/\/doi.org\/10.1093\/eurheartj\/ehac361.","journal-title":"Eur Heart J"},{"issue":"4","key":"2938_CR6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jacc.2022.11.042","volume":"81","author":"S Tsimikas","year":"2023","unstructured":"Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a): Insights from the emerging therapeutic landscape. J Am Coll Cardiol. 2023;81(4):411\u201326. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.042.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2938_CR7","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jama.2009.1063","volume":"302","author":"The Emerging Risk Factors Collaboration","year":"2009","unstructured":"The Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302(4):412\u201323. https:\/\/doi.org\/10.1001\/jama.2009.1063.","journal-title":"JAMA"},{"issue":"3","key":"2938_CR8","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jacl.2016.02.018","volume":"10","author":"S Varvel","year":"2016","unstructured":"Varvel S, McConnell JP, Tsimikas S, Marcovina SM. Prevalence of elevated lipoprotein(a) mass levels and patient thresholds in 532,000 patients in the United States. J Clin Lipidol. 2016;10(3):556\u201365. https:\/\/doi.org\/10.1016\/j.jacl.2016.02.018.","journal-title":"J Clin Lipidol"},{"issue":"39","key":"2938_CR9","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","volume":"43","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925\u201346. https:\/\/doi.org\/10.1093\/eurheartj\/ehac361.","journal-title":"Eur Heart J"},{"issue":"1","key":"2938_CR10","doi-asserted-by":"publisher","first-page":"dyae166","DOI":"10.1093\/ije\/dyae166","volume":"54","author":"K S\u00e4\u00e4ksj\u00e4rvi","year":"2025","unstructured":"S\u00e4\u00e4ksj\u00e4rvi K, Elonheimo HM, Ikonen J, et al. Cohort Profile: Healthy Finland Survey. Int J Epidemiol. 2025;54(1):dyae166. https:\/\/doi.org\/10.1093\/ije\/dyae166.","journal-title":"Int J Epidemiol"},{"issue":"23","key":"2938_CR11","doi-asserted-by":"publisher","first-page":"e016318","DOI":"10.1161\/JAHA.119.016318","volume":"9","author":"P Willeit","year":"2020","unstructured":"Willeit P, Yeang C, Moriarty PM, et al. Low-density lipoprotein cholesterol corrected for lipoprotein(a) cholesterol, risk thresholds, and cardiovascular events. J Am Heart Assoc. 2020;9(23):e016318. https:\/\/doi.org\/10.1161\/JAHA.119.016318.","journal-title":"J Am Heart Assoc"},{"key":"2938_CR12","unstructured":"World Health Organization. Waist circumference and waist\u2013hip ratio: report of a WHO expert consultation, Geneva, 8\u201311 December 2008. Geneva: WHO. 2011. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/44583\/9789241501491_eng.pdf"},{"key":"2938_CR13","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41366-024-01485-8","volume":"48","author":"L Wang","year":"2024","unstructured":"Wang L, Ding H, Deng Y, et al. Associations of obesity indices change with cardiovascular outcomes: a dose-response meta-analysis. Int J Obes (Lond). 2024;48:635\u201345. https:\/\/doi.org\/10.1038\/s41366-024-01485-8.","journal-title":"Int J Obes (Lond)"},{"issue":"9","key":"2938_CR14","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1017\/S0007114521000064","volume":"126","author":"R Xue","year":"2021","unstructured":"Xue R, Li Q, Geng Y, et al. Abdominal obesity and risk of CVD: a dose\u2013response meta-analysis of thirty-one prospective studies. Br J Nutr. 2021;126(9):1420\u201330. https:\/\/doi.org\/10.1017\/S0007114521000064.","journal-title":"Br J Nutr"},{"key":"2938_CR15","unstructured":"R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. 2024. Available from: https:\/\/www.R-project.org\/[1] https:\/\/www.programmingr.com\/examples\/neat-tricks\/r-citation\/."},{"key":"2938_CR16","unstructured":"Lumley T. survey: analysis of complex survey samples. R package version 4.4; 2024. Available from: https:\/\/CRAN.R-project.org\/package=survey"},{"key":"2938_CR17","volume-title":"Stata Statistical Software: Release 16. College Station","author":"StataCorp","year":"2019","unstructured":"StataCorp. Stata Statistical Software: Release 16. College Station. TX: StataCorp LLC; 2019."},{"issue":"15","key":"2938_CR18","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.1080\/02664763.2016.1144725","volume":"43","author":"T H\u00e4rk\u00e4nen","year":"2016","unstructured":"H\u00e4rk\u00e4nen T, Karvanen J, Tolonen H, Lehtonen R, et al. Systematic handling of missing data in complex study designs - experiences from the Health 2000 and 2011 Surveys. J Appl Stat. 2016;43(15):2772\u201390. https:\/\/doi.org\/10.1080\/02664763.2016.1144725.","journal-title":"J Appl Stat"},{"issue":"5","key":"2938_CR19","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jacc.2020.05.061","volume":"76","author":"T Zeller","year":"2020","unstructured":"Zeller T, Waldeyer C, Teupser D, et al. Lipoprotein(a), Cardiovascular Disease, and Contemporary Risk Prediction Models. J Am Coll Cardiol. 2020;76(5):556\u201367. https:\/\/doi.org\/10.1016\/j.jacc.2020.05.061.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2938_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1161\/CIRCULATIONAHA.122.060667","volume":"147","author":"O Raitakari","year":"2023","unstructured":"Raitakari O, Kartiosuo N, Pahkala K, et al. Lipoprotein(a) in youth and prediction of major cardiovascular outcomes in adulthood. Circulation. 2023;147(1):23\u201331. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.060667.","journal-title":"Circulation"},{"key":"2938_CR21","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382:244\u201355. https:\/\/doi.org\/10.1056\/NEJMoa1905239.","journal-title":"N Engl J Med"},{"issue":"22","key":"2938_CR22","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2009.814","volume":"301","author":"PR Kamstrup","year":"2009","unstructured":"Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331\u20139. https:\/\/doi.org\/10.1001\/jama.2009.814.","journal-title":"JAMA"},{"issue":"23","key":"2938_CR23","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","volume":"31","author":"BG Nordestgaard","year":"2010","unstructured":"Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844\u201353. https:\/\/doi.org\/10.1093\/eurheartj\/ehq386.","journal-title":"Eur Heart J"},{"key":"2938_CR24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.pcad.2024.08.004","volume":"86","author":"B Sosnowska","year":"2024","unstructured":"Sosnowska B, Lewek J, Adach W, et al. The prevalence, patients\u2019 characteristics, and hyper-Lp(a)-emia risk factors in the Polish population: The first results from the PMMHRI-Lp(a) Registry. Prog Cardiovasc Dis. 2024;86:54\u201361.","journal-title":"Prog Cardiovasc Dis"},{"key":"2938_CR25","unstructured":"Eurostat. Causes of death \u2013 diseases of the circulatory system, residents, 2021. [Internet]. Available from: https:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php?title=File:Causes_of_death_\u2013_diseases_of_the_circulatory_system,_residents,_2021_Health2024.png"},{"issue":"2","key":"2938_CR26","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/HYPERTENSIONAHA.122.20189","volume":"80","author":"R Rikhi","year":"2023","unstructured":"Rikhi R, Bhatia HS, Schaich CL, et al. Association of Lp(a) and hypertension in primary prevention of cardiovascular disease: the MESA. Hypertension. 2023;80(2):352\u201360. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.122.20189.","journal-title":"Hypertension"},{"issue":"1","key":"2938_CR27","doi-asserted-by":"publisher","first-page":"14433","DOI":"10.1038\/s41598-024-65231-w","volume":"14","author":"N Vazquez-Agra","year":"2024","unstructured":"Vazquez-Agra N, Cruces-Sande A, Barbosa-Gouveia S, et al. Assessing the relationship between lipoprotein(a) levels and blood pressure among hypertensive patients beyond conventional measures. An observational study. Sci Rep. 2024;14(1):14433. https:\/\/doi.org\/10.1038\/s41598-024-65231-w. Published 2024 Jun 23.","journal-title":"Sci Rep"},{"key":"2938_CR28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11906-021-01161-6","volume":"23","author":"NC Ward","year":"2021","unstructured":"Ward NC, Nolde JM, Chan J, et al. Lipoprotein(a) and hypertension. Curr Hypertens Rep. 2021;23:44. https:\/\/doi.org\/10.1007\/s11906-021-01161-6.","journal-title":"Curr Hypertens Rep"},{"issue":"1","key":"2938_CR29","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12933-024-02348-2","volume":"23","author":"A Shiyovich","year":"2024","unstructured":"Shiyovich A, Berman AN, Besser SA, et al. Lipoprotein(a) as a cardiovascular risk factor among patients with and without diabetes mellitus: the Mass General Brigham Lp(a) Registry. Cardiovasc Diabetol. 2024;23(1):257. https:\/\/doi.org\/10.1186\/s12933-024-02348-2.","journal-title":"Cardiovasc Diabetol"},{"key":"2938_CR30","doi-asserted-by":"publisher","first-page":"119179","DOI":"10.1016\/j.atherosclerosis.2025.119179","volume":"404","author":"R Rikhi","year":"2025","unstructured":"Rikhi R, Haidar A, Bhatia HS, et al. Association of lipoprotein(a) and diabetes in primary prevention of coronary heart disease: the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2025;404:119179. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.119179.","journal-title":"Atherosclerosis"},{"issue":"24","key":"2938_CR31","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2019.10.019","volume":"74","author":"DF Gudbjartsson","year":"2019","unstructured":"Gudbjartsson DF, Thorgeirsson G, Sulem P, et al. Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes. J Am Coll Cardiol. 2019;74(24):2982\u201394. https:\/\/doi.org\/10.1016\/j.jacc.2019.10.019.","journal-title":"J Am Coll Cardiol"},{"key":"2938_CR32","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0000000000000996","author":"MG Corral Matta","year":"2025","unstructured":"Corral Matta MG, Schreier L. Are lipoprotein(a) levels decreased in insulin resistance and type 2 diabetes? Curr Opin Lipidol. 2025. https:\/\/doi.org\/10.1097\/MOL.0000000000000996.","journal-title":"Curr Opin Lipidol"},{"key":"2938_CR33","unstructured":"Erlinge D, Schwartz GG, Barkas F et al. Global variation in lipoprotein(a) levels and plaque vulnerability: insights from the PROSPECT II substudy and international CHD cohort. J Am Coll Cardiol. 2025 May 28. [Epub ahead of print]. Available from: https:\/\/www.acc.org\/Latest-in-Cardiology\/Journal-Scans\/2025\/05\/28\/13\/17\/New-Research-Adds-to-Growing-Evidence"},{"issue":"4","key":"2938_CR34","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2337\/dc24-2110","volume":"48","author":"GG Schwartz","year":"2025","unstructured":"Schwartz GG, Szarek M, Jukema JW, et al. Risk of incident diabetes related to lipoprotein(a), LDL cholesterol, and their changes with alirocumab: post hoc analyses of the ODYSSEY OUTCOMES randomized trial. Diabetes Care. 2025;48(4):596\u2013604. https:\/\/doi.org\/10.2337\/dc24-2110.","journal-title":"Diabetes Care"},{"key":"2938_CR35","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12933-024-02389-7","volume":"23","author":"M Lejawa","year":"2024","unstructured":"Lejawa M, Go\u0142awski M, Fronczek M, et al. Causal associations between insulin and Lp(a) levels in Caucasian population: a Mendelian randomization study. Cardiovasc Diabetol. 2024;23:316. https:\/\/doi.org\/10.1186\/s12933-024-02389-7.","journal-title":"Cardiovasc Diabetol"},{"key":"2938_CR36","doi-asserted-by":"publisher","unstructured":"Jamialahmadi T, Mirhadi E, Reiner \u017d, Abass KS, Almahmeed W, Virani S, Sahebkar S. A. Effects of Pioglitazone On Lipoprotein(a): A Meta-analysis. Curr Atheroscler Rep. 2025;27(1):94. https:\/\/doi.org\/10.1007\/s11883-025-01346-3. PMID: 41003906.","DOI":"10.1007\/s11883-025-01346-3"},{"key":"2938_CR37","doi-asserted-by":"publisher","first-page":"154441","DOI":"10.1016\/j.metabol.2020.154441","volume":"115","author":"ME Pich\u00e9","year":"2021","unstructured":"Pich\u00e9 ME, Tardif I, Auclair A, Poirier P. Effects of bariatric surgery on lipid-lipoprotein profile. Metabolism. 2021;115:154441. https:\/\/doi.org\/10.1016\/j.metabol.2020.154441.","journal-title":"Metabolism"},{"key":"2938_CR38","doi-asserted-by":"publisher","unstructured":"Jamialahmadi T, Reiner \u017d, Alidadi M et al. The Effect of Bariatric Surgery on Circulating Levels of Lipoprotein (a): A Meta-analysis. Biomed Res Int. 2022;2022:8435133. Published 2022 Aug 17. https:\/\/doi.org\/10.1155\/2022\/8435133","DOI":"10.1155\/2022\/8435133"},{"key":"2938_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2025.119218","author":"F Kronenberg","year":"2025","unstructured":"Kronenberg F, Bedlington N, Ademi Z, et al. The Brussels International Declaration on Lipoprotein(a) Testing and Management. Atherosclerosis. 2025. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.119218.","journal-title":"Atherosclerosis"},{"key":"2938_CR40","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s12170-025-00759-8","volume":"19","author":"C De Los Reyes","year":"2025","unstructured":"De Los Reyes C, Rikhi RR, Doherty S, et al. Current clinical trials for treating elevated lipoprotein(a). Curr Cardiovasc Risk Rep. 2025;19:7. https:\/\/doi.org\/10.1007\/s12170-025-00759-8.","journal-title":"Curr Cardiovasc Risk Rep"},{"issue":"7","key":"2938_CR41","doi-asserted-by":"publisher","first-page":"919","DOI":"10.3390\/ph16070919","volume":"16","author":"JM Farina","year":"2023","unstructured":"Farina JM, Pereyra M, Mahmoud AK, et al. Current management and future perspectives in the treatment of Lp(a) with a focus on the prevention of cardiovascular diseases. Pharmaceuticals (Basel). 2023;16(7):919. https:\/\/doi.org\/10.3390\/ph16070919.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"2938_CR42","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S2213-8587(19)30388-2","volume":"8","author":"N Wang","year":"2020","unstructured":"Wang N, Fulcher J, Abeysuriya N, et al. Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomized trials including 327 037 participants. Lancet Diabetes Endocrinol. 2020;8(1):36\u201349.","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-026-02938-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-026-02938-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-026-02938-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:35:05Z","timestamp":1778632505000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12944-026-02938-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2938"],"URL":"https:\/\/doi.org\/10.1186\/s12944-026-02938-x","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The Healthy Finland Study was approved by the HUS Regional Committee on Medical Research Ethics (HUS\/900\/2022) in September 2022. All participants signed an informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AV has received consultancy fees from Amgen and Novartis. PTK has received consultancy fees, lecture honoraria, and\/or travel fees from Amgen, Novartis, Raisio Group, Amarin and Sanofi.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"128"}}